Recent Press Releases

Scientific Clinical | Phase I study results show first-in-class NBTXR3 could present as a valuable option for patients with hepatocellular carcinoma or liver metastasis
Financial | Nanobiotix announces half year financial statements of june 30, 2019
Scientific Clinical | Nanobiotix announces publication of phase III soft tissue sarcoma data for first-in-class NBTXR3 in the Lancet Oncology

ALL NANOBIOTIX PRESS RELEASE

Overview_News_1


NBTXR3 First in Class Radioenhancer

Physical Mode of Action that could work across all solid tumors to enhance radiotherapy efficacy.

Only one administration

Fits into existing standard of care :

  • No change in equipment
  • No change in current patient flow
  • No change in protocol
  • One product addressing areas of high unmet medical needs.


    See more

    Events

    5 November 2019

    Kepler Cheuvreux Biotech Day

    More info
    November 6-10, 2019

    SITC 2019

    More info

    JOIN US


    "Being part of Nanobiotix is a privilege. The privilege of exploring beyond the edge of science and challenging established and existing limits for the good of humankind. The privilege of being part of an extraordinary adventure to enable people to live a better life. The privilege of expanding life."

    Anne-Juliette Hermant
    Chief People Officer
     

    Download our latest
    Corporate Presentation

     
    English